# HHS Opens a Conditional 503A Path for Six Peptides: What Changed on October 28, 2026
> Disclaimer: PeptIQ is not a medical provider or law firm. This article is educational only. It does not tell you what to buy, inject, or prescribe. Regulatory text changes quickly. Work with a licensed clinician for any treatment decision, and verify the current Federal Register notice and FDA compounding safety-risk page before acting on access claims.
On October 28, 2026, the U.S. Department of Health and Human Services published an interim Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Under this policy, HHS states that it will not take enforcement action against eligible 503A compounding for six named peptides, provided all policy conditions are met, while FDA continues rulemaking on the Section 503A bulk drug substances list.
That sentence is dense on purpose. Most social posts will shorten it to "peptides are legal now." That shorthand is wrong in ways that matter for patients, prescribers, and pharmacies.
This guide stays close to the primary documents and reputable reporting summarized in our research file (October 29, 2026). Where timing or vote details remain unsettled, we label them uncertain rather than guessing.
What actually changed
Before October 28: The six peptides were generally treated as nominated but withdrawn for the 503A bulks list framework. In plain terms, they were not on the list in 21 CFR 216.23(a), and compounding them under 503A carried serious enforcement risk unless another lawful basis applied.
After October 28 (policy announcement): HHS created a temporary enforcement-discretion lane for patient-specific 503A compounding of those six substances only when every condition in the policy is satisfied. The substances are not added to the 503A bulks list by this action.
Important boundaries from the policy framing:
| Statement | Accurate? |
|---|---|
| HHS issued the policy under Secretary authority | Yes |
| The policy is FDA drug approval for these peptides | No |
| The six peptides are added to the 503A bulks list | No |
| The policy applies to 503B outsourcing facilities | No |
| The policy applies to research-use-only (RUO) chemical sellers | No |
| The policy applies to dietary supplements | No |
| Qualifying 503A pharmacies / physicians may compound with enforcement discretion | Yes, if all conditions met |
Enforcement discretion is an agency statement about enforcement priorities. It is not a guarantee that every state board, payer, or hospital will agree. It can be revised or withdrawn if HHS sees safety or quality signals.
Federal Register timing (read carefully)
The document is scheduled for Federal Register publication on October 30, 2026 (document 2026-22192). A public comment period is expected to open about two weeks after publication.
Effective date: uncertain. Some news coverage (for example NBC News) reports that pharmacies may begin operating under the policy immediately after the October 28 announcement. The formal Federal Register publication date remains October 30, 2026. Pharmacies and counsel should read the published text, not only press summaries.
Duration: The policy lasts until each peptide is addressed by a final FDA rule (included on or excluded from the bulks list). Peptides can exit the discretion lane at different times.
Context: July 2026 PCAC and FDA staff
In July 2026, the Pharmacy Compounding Advisory Committee (PCAC) reviewed several of these nominations. Reporting from NPR, the Associated Press, and Fox Rothschild describes a split record: PCAC recommended moving forward on the six peptides covered here, while FDA CDER scientists recommended against including them on the 503A bulks list.
PeptIQ does not cite specific PCAC vote tallies in this article. Published FDA meeting minutes are the authoritative source for counts; secondary tables disagree on at least one substance. Treat advisory votes as context, not as compounding permission by themselves.
The six peptides: form, routes, and status shift
Appendix A and Appendix B of the HHS policy tie enforcement discretion to specific bulk identities and routes. Compounding outside those definitions is not covered.
| Peptide | Bulk form in policy | Permitted routes | 503A under policy | 503B under policy |
|---|---|---|---|---|
| BPC-157 | acetate | subcutaneous, intramuscular, oral, topical | Conditional discretion | Not covered |
| TB-500 | acetate | subcutaneous or intramuscular injection | Conditional discretion | Not covered |
| Epitalon | acetate | subcutaneous or intramuscular, intermittent courses | Conditional discretion | Not covered |
| Semax | free base | intranasal | Conditional discretion | Not covered |
| KPV | acetate | topical, oral | Conditional discretion | Not covered |
| MOTS-c | acetate | subcutaneous or intramuscular | Conditional discretion | Not covered |
Before the policy: Each substance above was withdrawn from the 503A bulks nomination path (formerly Category 2 in the interim policy vocabulary) and was not compoundable under the bulks-list framework.
After the policy (conditional): HHS may refrain from enforcement against qualifying 503A compounding that matches Appendix A/B. That is not the same as FDA affirming safety or efficacy for every online use case.
Route discipline matters clinically and legally. A pharmacy compounding Semax for injection when the policy specifies intranasal free base, or Epitalon on a continuous schedule when the policy specifies intermittent courses, falls outside the stated discretion scope.
PeptIQ does not provide dosing or reconstitution instructions here. For education on tracking and calculators after a clinician defines a lawful product, see the reconstitution calculator and in-app PeptIQ AI (educational Q&A, not prescribing).
The ten conditions: all required
HHS lists ten conditions that must all be met for the discretion to apply, plus ordinary Section 503A and FD&C Act requirements. Partial compliance is not described as sufficient.
- Listed substance: The bulk drug substance appears in Appendix A of the policy.
- Identity and route: Compounding matches Appendix B (correct salt/form and permitted route).
- 510(k)-registered source with valid COA: Bulk from a FDA-registered facility with a certificate of analysis covering identity, purity, potency, endotoxin, heavy metals, microbes, and impurities.
- Original manufacturer on COA: Manufacturer is FDA-registered and CGMP-compliant, with location on the COA. Repackers must validate the vendor.
- Adverse event reporting: Report serious adverse events and quality issues to FDA MedWatch and relevant state authorities.
- Patient-specific prescription: Valid prescription for an identified individual patient.
- Single active ingredient: One API only in the compounded preparation (no multi-API blends under this discretion unless otherwise lawful outside this policy).
- Label statement: Label includes "This is a compounded drug product. Not for resale."
- Oral bioavailability documentation: Oral forms require documented bioavailability (applies to BPC-157 oral and KPV oral in this set).
- Device limits: The only co-packaged device is an FDA-cleared syringe when applicable.
Think of the policy as a checklist bridge between gray-market RUO vials and eventual bulks-list rulemaking. It pushes compounders toward pharmacy-grade documentation without granting FDA approval.
What is NOT covered (still unchanged)
The discretion policy does not reset the entire peptide compounding landscape. Many popular names remain outside this action.
Framework exclusions
- 503B outsourcing facilities (office-stock compounding) — not in this policy.
- RUO chemical vendors — still not lawful human drug sources; the policy is aimed at licensed 503A channels, not research-label sellers.
- Dietary supplement marketing — unchanged.
- Bulks list status — substances remain off 21 CFR 216.23(a) until formal rulemaking says otherwise.
Peptides still not compoundable under this action (examples)
The table below reflects FDA safety-risk / nomination status as summarized in our October 2026 research file (cross-checked against the FDA safety-risk bulk substances page). It is not exhaustive of every peptide name online.
